The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Ryan Barbara since 2022.
This trader's CIK number is 1827169.
At the time of last reporting, Ryan Barbara was the Director of Indivior Pharmaceuticals, Inc.. (stock ticker symbol INDV).
Also see all insider trading activities at Indivior Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | INKT | 0 | $0 | 500 | $5,425 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | INVO | 10,526 | $9,999 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | INDV | 814 | $28,686 | 0 | $0 | 0 | $0 |
1. Mink Therapeutics, Inc. (INKT)
2. Invo Fertility, Inc. (INVO)
3. Indivior Pharmaceuticals, Inc. (INDV)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-03-02 | INKT | Sale | 100 | 10.83 | 1,082 |
| 2026-02-27 | INKT | Sale | 400 | 10.86 | 4,343 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-06-01 | INVO | Buy | 10,526 | .95 | 9,999 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-03-13 | INDV | Buy | 8 | 31.09 | 248 |
| 2026-03-09 | INDV | Buy | 31 | 32.56 | 1,009 |
| 2026-01-05 | INDV | Buy | 775 | 35.39 | 27,429 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ryan Barbara (Director of Indivior Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.